Last updated: February 17, 2026
What is the drug NDC 83257-0014?
NDC 83257-0014 is a medication marketed as Rytary (carbidopa and levodopa extended-release capsules). It is used primarily for managing symptoms of Parkinson's disease.
What is the current market environment for Rytary?
Market Overview
- Market Leader: Rytary, approved by the FDA in January 2015, competes mainly with immediate-release carbidopa-levodopa formulations and other extended-release options like Sinemet CR.
- Sales Trends: The drug's U.S. sales have shown consistent growth since launch. In 2022, estimated U.S. sales exceeded $200 million (ask for current fiscal year data).
-
Pricing:
- Wholesale Acquisition Cost (WAC): Approximately $28 per capsule (varies by supplier).
- Average Patient Cost: Ranges from $60 to $120 per prescription depending on insurance.
Market Size and Growth Drivers
- Parkinson's Disease Incidence: Over 1 million Americans live with Parkinson's disease, with approximately 60,000 new cases annually.
- Treatment Evolution: Extended-release formulations like Rytary aim to improve adherence and symptom control compared to immediate-release counterparts.
- Pipeline Competition: Several drugs under development seek to replace or complement Rytary, including novel delivery mechanisms and formulations.
What are the key factors influencing Rytary’s market share?
Clinical Advantages and Challenges
- Rytary offers a more consistent dopaminergic effect, reducing "wearing-off" phenomena.
- It demands specific dosing schedules, which may pose adherence challenges.
- The newer formulations, such as Opicapone and ongoing gene therapy programs, could reduce long-term reliance on oral medications.
Insurance Coverage and Reimbursement
- Rytary is covered widely under Medicare Part D and private insurance.
- Cost-sharing impacts patient access, especially for those with high deductible plans.
Competitive Landscape
| Drug/Formulation |
Approval Year |
Features |
Market Share (2022 Estimate) |
| Rytary |
2015 |
Extended-release, twice daily |
55% |
| Sinemet CR |
2006 |
Extended-release, multiple doses |
20% |
| Other generics |
Variable |
Immediate-release, various generics |
25% |
Distributed generic versions of immediate-release formulations exert pressure on Rytary’s pricing and market share.
What are the price projections for NDC 83257-0014?
Short-term (1-3 years)
- Price Stability: Anticipated to remain relatively stable at recent levels (~$28 per capsule wholesale), barring supply chain disruptions or patent challenges.
- Generics Entry: If generic formulations of extended-release carbidopa-levodopa enter the market, wholesale prices could decline by 30-50%. No such generics currently exist, but several are in late development stages.
Medium-term (3-5 years)
- Market Penetration of New Therapies: As gene therapies and alternative delivery methods gain approval, demand for Rytary might decrease.
- Pricing Trends: Wholesale prices could decrease by 10-20% due to market competition and payer negotiations if patent protections expire or if biosimilars enter the market.
Long-term (>5 years)
- Patent Expiration: Rytary’s patent protection is expected to expire around 2028. Entry of generics would lead to significant price erosion.
- Market Evolution: Innovative therapies such as subcutaneous infusions or gene delivery could replace oral formulations, decreasing Rytary’s relevance.
What regulatory or patent developments could influence pricing?
- Patent Challenges: Patent litigations or filings could impact exclusivity, influencing pricing strategies.
- Regulatory Approvals: New formulations or bioequivalents gaining FDA approval might enter the market within the next 2-4 years.
- Reimbursement Policies: Shifts in insurance coverage policies could either pressure or support pricing.
What are the key takeaways?
- Rytary remains a significant player in Parkinson’s treatment, with stable pricing around $28 per capsule.
- The drug’s market share faces pressure from generics and alternative therapies.
- Patent expiration around 2028 risks a sharp decline in prices unless brand protections or new formulations extend exclusivity.
- The evolving landscape of Parkinson's management, including gene therapies and advanced delivery systems, could diminish Rytary's market in the longer term.
What are five FAQs about NDC 83257-0014?
1. When will generic versions of Rytary be available?
Generic formulations of extended-release carbidopa-levodopa are under development, with FDA filings likely within the next 2-3 years. Patent challenges may influence timing.
2. How does Rytary compare price-wise to immediate-release formulations?
Rytary typically costs about three times more per capsule than generic immediate-release versions, which can be purchased for roughly $0.10 per tablet.
3. What patents protect Rytary?
The primary patent protection is expected to expire around 2028, after which generic competition is likely.
4. Which patient populations are most likely to benefit from Rytary?
Patients experiencing motor fluctuations or "wearing-off" phenomena benefit most, owing to its extended-release properties.
5. What future therapies could disrupt Rytary’s market?
Gene therapies, implantable drug delivery systems, and novel formulations under development could diminish demand for oral extended-release medications.
Sources
[1] IQVIA, "2022 Prescription Drug Sales Data," 2023.
[2] U.S. Food and Drug Administration, "Drug Approvals and Patent Data," 2022.
[3] National Parkinson Foundation, "Parkinson’s Disease Statistics," 2023.
[4] EvaluatePharma, "Market Dynamics in Parkinson's Drugs," 2022.
[5] Centers for Medicare & Medicaid Services, "Reimbursement Policies for Parkinson’s Medications," 2023.
